News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

Scrip

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

All Stories

All
News
Press Releases
News

Influential Women 2023: Svetlana Lucas, Chief Business Officer, Scribe Therapeutics

October 6, 2023

San Francisco Business Times

Read Now
News

This Scientist Is Building Custom Gene-Editing Tools

July 25, 2023

Forbes

Read Now
News

Scribe Therapeutics' Gene-Editing Tech Attracts Pharma Partners

July 20, 2023

Wall Street Journal

Read Now
News

Scribe Therapeutics and Sanofi collaborate on in vivo therapies for sickle cell disease

July 18, 2023

BioWorld

Read Now
News

Sanofi expands collaboration with Scribe on CRISPR genome editing

July 18, 2023

Seeking Alpha

Read Now
News

East Bay's Scribe Therapeutics lands 2nd big deal with Sanofi, this one aimed initially at sickle cell disease

July 18, 2023

San Francisco Business Times

Read Now
Press release

Scribe Therapeutics Appoints Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, and Dr. Maria Mirotsou as Vice President of Discovery Biology

December 20, 2023

Read Now
Press release

Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases

July 17, 2023

Read Now
Press release

Scribe Therapeutics to Participate in Upcoming Investor Conferences in May and June

May 22, 2023

Read Now
Press release

Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 19, 2023

Read Now
Press release

Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases

May 16, 2023

Read Now
Press release

Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 2, 2023

Read Now

Publications and presentations